JP2018501276A - 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 - Google Patents

非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 Download PDF

Info

Publication number
JP2018501276A
JP2018501276A JP2017535411A JP2017535411A JP2018501276A JP 2018501276 A JP2018501276 A JP 2018501276A JP 2017535411 A JP2017535411 A JP 2017535411A JP 2017535411 A JP2017535411 A JP 2017535411A JP 2018501276 A JP2018501276 A JP 2018501276A
Authority
JP
Japan
Prior art keywords
inhibitor
ring
membered
sulfur
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017535411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501276A5 (enExample
Inventor
ジェラルディン シー． ハリマン，
ジェラルディン シー． ハリマン，
エイチ． ジェイムズ ハーウッド，
エイチ． ジェイムズ ハーウッド，
ロサーナ カペラー−リーベルマン，
ロサーナ カペラー−リーベルマン，
ウィリアム エフ． ウェストリン，
ウィリアム エフ． ウェストリン，
Original Assignee
ギリアド アポロ， エルエルシー
ギリアド アポロ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアド アポロ， エルエルシー, ギリアド アポロ， エルエルシー filed Critical ギリアド アポロ， エルエルシー
Publication of JP2018501276A publication Critical patent/JP2018501276A/ja
Publication of JP2018501276A5 publication Critical patent/JP2018501276A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017535411A 2015-01-09 2016-01-08 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 Withdrawn JP2018501276A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101726P 2015-01-09 2015-01-09
US62/101,726 2015-01-09
PCT/US2016/012673 WO2016112305A1 (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020072689A Division JP2020109130A (ja) 2015-01-09 2020-04-15 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法

Publications (2)

Publication Number Publication Date
JP2018501276A true JP2018501276A (ja) 2018-01-18
JP2018501276A5 JP2018501276A5 (enExample) 2019-02-14

Family

ID=56356482

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017535411A Withdrawn JP2018501276A (ja) 2015-01-09 2016-01-08 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
JP2020072689A Pending JP2020109130A (ja) 2015-01-09 2020-04-15 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020072689A Pending JP2020109130A (ja) 2015-01-09 2020-04-15 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法

Country Status (13)

Country Link
US (2) US20180021341A1 (enExample)
EP (2) EP3597271A1 (enExample)
JP (2) JP2018501276A (enExample)
KR (1) KR20170102299A (enExample)
CN (1) CN107106873A (enExample)
AU (1) AU2016205138A1 (enExample)
BR (1) BR112017014341A2 (enExample)
CA (1) CA2972919A1 (enExample)
EA (2) EA201892625A1 (enExample)
HK (2) HK1243369A1 (enExample)
MX (1) MX2017008844A (enExample)
SG (1) SG11201705361PA (enExample)
WO (1) WO2016112305A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522247A (ja) * 2018-04-24 2021-08-30 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 肝疾患における好中球エラスターゼ阻害薬の使用
JPWO2021235508A1 (enExample) * 2020-05-21 2021-11-25
JP2022513101A (ja) * 2018-11-20 2022-02-07 中国医▲薬▼研究▲開▼▲発▼中心有限公司 スピロ環系化合物及びその医薬用途
JP2022540560A (ja) * 2019-07-02 2022-09-16 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 立体配置を有するチエノピリミジン誘導体及び薬物におけるその応用
JP2023544220A (ja) * 2020-11-17 2023-10-20 インベンティバ 肝疾患を治療するための併用療法

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
ES2734713T3 (es) 2015-07-06 2019-12-11 Gilead Sciences Inc Moduladores Cot y métodos de utilización de los mismos
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
US20170166582A1 (en) * 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
SG10202104575WA (en) 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
JP2019537607A (ja) * 2016-11-10 2019-12-26 ガルメド リサーチ アンド ディベロップメント リミテッド 非アルコール性脂肪性肝疾患の患者における線維化の抑制
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CA3152584C (en) * 2016-11-10 2024-02-13 Galmed Research And Development Ltd. Treatment for fibrosis
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AU2018209006B2 (en) * 2017-01-22 2021-04-22 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
CN110431144B (zh) * 2017-03-24 2022-08-05 浙江海正药业股份有限公司 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途
US20180311244A1 (en) * 2017-03-28 2018-11-01 Gilead Sciences, Inc. Methods of treating liver disease
ES2982801T3 (es) * 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
EP3609496A1 (en) * 2017-04-12 2020-02-19 Gilead Sciences, Inc. Methods of treating liver disease
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
EP3609523B1 (en) * 2017-04-24 2022-03-02 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
US20200129511A1 (en) * 2017-06-19 2020-04-30 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash
WO2019015583A1 (en) * 2017-07-17 2019-01-24 Nanjing Ruijie Pharmatech Co., Ltd. NOVEL COMPOUNDS AND THEIR USES AS ACC INHIBITORS
EP3660023B1 (en) * 2017-07-26 2023-03-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Thienopyrimidinedione compounds as acc inhibitors and use thereof
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
US11542256B2 (en) 2017-09-03 2023-01-03 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
US11033601B2 (en) * 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
AU2019216264B2 (en) 2018-01-31 2023-08-31 Heparegenix Gmbh Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US20210113561A1 (en) * 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2019243315A1 (en) 2018-06-21 2019-12-26 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202012732UA (en) 2018-07-16 2021-02-25 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
JP7161605B2 (ja) 2018-08-31 2022-10-26 ファイザー・インク Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ
CA3111025C (en) * 2018-09-06 2023-10-31 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2020208205A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法
JP7629442B2 (ja) 2019-07-29 2025-02-13 ヘパリジェニックス ゲーエムベーハー 肝臓再生を促進または肝細胞死を縮減もしくは防止するためのヘテロアリール置換ピラゾロ－ピリジンタンパク質キナーゼ阻害剤
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN110628810B (zh) * 2019-08-13 2022-06-28 浙江大学 一种提高植物光合效率的方法
CN114340632B (zh) * 2019-08-30 2024-09-17 赛特瑞恩股份有限公司 用于治疗或预防非酒精性脂肪性肝炎（nash）的药物组合物
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
EP4126862B1 (en) 2020-04-02 2025-05-21 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
ES3061522T3 (en) 2021-03-29 2026-04-06 Gilead Sciences Inc Khk inhibitors
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2023034381A1 (en) * 2021-08-31 2023-03-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Quantitative systems pharmacology methods for identifying therapeutics for disease states
WO2023047203A1 (en) * 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
JPWO2023090411A1 (enExample) 2021-11-19 2023-05-25
EP4731212A1 (en) * 2023-06-20 2026-04-29 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
KR20250155468A (ko) * 2024-04-22 2025-10-30 연세대학교 원주산학협력단 CCR2 억제제와 TGF-β 수용체 억제제의 병용투여를 통한 대사이상관련 지방간염 치료 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2189458A1 (en) * 2008-10-30 2010-05-26 Janssen Pharmaceutica, N.V. Aryl amide compound as an acetyl coenzyme A carboxylase inhibitor
WO2014182951A1 (en) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2014182945A1 (en) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
JP2014533281A (ja) * 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155611A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
AU2014262636A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994128B1 (en) 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2189458A1 (en) * 2008-10-30 2010-05-26 Janssen Pharmaceutica, N.V. Aryl amide compound as an acetyl coenzyme A carboxylase inhibitor
JP2014533281A (ja) * 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2014182951A1 (en) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2014182945A1 (en) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522247A (ja) * 2018-04-24 2021-08-30 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 肝疾患における好中球エラスターゼ阻害薬の使用
JP2022513101A (ja) * 2018-11-20 2022-02-07 中国医▲薬▼研究▲開▼▲発▼中心有限公司 スピロ環系化合物及びその医薬用途
JP2022540560A (ja) * 2019-07-02 2022-09-16 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 立体配置を有するチエノピリミジン誘導体及び薬物におけるその応用
JP7374233B2 (ja) 2019-07-02 2023-11-06 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 立体配置を有するチエノピリミジン誘導体及び薬物におけるその応用
JPWO2021235508A1 (enExample) * 2020-05-21 2021-11-25
WO2021235508A1 (ja) * 2020-05-21 2021-11-25 塩野義製薬株式会社 脂肪性肝疾患の治療用医薬
US12521375B2 (en) 2020-05-21 2026-01-13 Shionogi & Co., Ltd. Pharmaceutical composition for treating fatty liver disease
JP7820294B2 (ja) 2020-05-21 2026-02-25 塩野義製薬株式会社 脂肪性肝疾患の治療用医薬
JP2023544220A (ja) * 2020-11-17 2023-10-20 インベンティバ 肝疾患を治療するための併用療法
JP2025060758A (ja) * 2020-11-17 2025-04-10 インベンティバ 肝疾患を治療するための併用療法

Also Published As

Publication number Publication date
BR112017014341A2 (pt) 2018-03-27
HK1243369A1 (zh) 2018-07-13
EP3242722A4 (en) 2018-07-11
WO2016112305A1 (en) 2016-07-14
AU2016205138A1 (en) 2017-07-13
CA2972919A1 (en) 2016-07-14
HK1246232A1 (zh) 2018-09-07
EP3242722A1 (en) 2017-11-15
JP2020109130A (ja) 2020-07-16
US20180021341A1 (en) 2018-01-25
MX2017008844A (es) 2018-03-14
SG11201705361PA (en) 2017-08-30
EA201791258A1 (ru) 2017-12-29
EP3597271A1 (en) 2020-01-22
KR20170102299A (ko) 2017-09-08
EA201892625A1 (ru) 2019-07-31
CN107106873A (zh) 2017-08-29
US20190381045A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
JP2020109130A (ja) 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
JP7479278B2 (ja) Ａｃｃ阻害剤を含む併用療法
JP2018501276A5 (enExample)
RU2473343C2 (ru) Лечение туберозного склероза
US7919484B2 (en) Combination therapy
JP2004525179A (ja) ジペプチジルペプチダーゼｉｖ阻害剤でのｉｉ型糖尿病の処置
EP3411026B1 (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
BR112014016808B1 (pt) Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
KR20080106455A (ko) 대사장애의 조합치료
CN108463224A (zh) sGC刺激剂用于胃肠功能障碍治疗的应用
BRPI0706528A2 (pt) combinação de inibidor de mtor e composto antifolato
WO2001000185A2 (en) 1,4-denzothiazepines to treat obesity related disorders
HK40021469A (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
WO2006132196A1 (ja) β３作動薬を含有する新規な医薬
WO2002022127A1 (en) Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
CN101374524A (zh) mTOR抑制剂和抗叶酸剂化合物的组合形式
WO2026035940A1 (en) Treatment of obesity
MX2008008944A (en) Combination of mtor inhibitor and antipolate compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191211

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200417